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ABSTRACT: Since the establishment of site-specific mutagenesis
of single amino acids to interrogate protein function in the 1970s,
biochemists have sought to tailor protein structure in the native
cell environment. Fine-tuning the chemical properties of proteins is
an indispensable way to address fundamental mechanistic
questions. Unnatural amino acids (UAAs) offer the possibility to
expand beyond the 20 naturally occurring amino acids in most
species and install new and useful chemical functions. Here, we
review the literature about advances in UAA incorporation
technology from chemoenzymatic aminoacylation of modified
tRNAs to in vitro translation systems to genetic encoding of UAAs
in the native cell environment and whole organisms. We discuss
innovative applications of the UAA technology to challenges in bioengineering and medicine.
A grand challenge for the field of biochemistry is a generalmethod for tailoring protein structure to address biological
mechanism in the native cellular environment and to endow
cells with new functions for future engineering applications.
Advances in molecular biology in the 1970s made site-specific
mutagenesis of single amino acids to probe protein function an
everyday reality for researchers. Expanding the mutagenesis
repertoire beyond the 20 naturally occurring amino acids in
most species, unnatural amino acids (UAAs) enable site-specific
installation of new and useful chemical functions, fluorescence,
ligand binding, cross-linking, or photocaging, for example. There
are still challenges to UAA mutagenesis being an everyday
technique for biochemists. In this Perspective, we highlight the
2013 work of Chatterjee and Schultz, key historical papers in the
field, and key perspective papers that illustrate future directions
being charted by researchers in the field. This Perspective is not
meant to stand in for comprehensive reviews published by
researchers in the field.1−4 Furthermore, we acknowledge that
there are several exciting technologies that have been developed
over the past several decades for chemical modification of
proteins; we speak to only the UAA technology here. Chatterjee
et al. (Schultz)5 is a landmark study demonstrating a streamlined
plasmid-based system for efficient multisite UAA incorporation
in one target protein in live bacterial cells.
Chatterjee et al. (Schultz)5 integrated conceptual advances in
orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA gener-
ation, multisite incorporation, and flexibility of codon usage in a
minimalist, optimized system for incorporation of UAAs in
living cells. UAAs are incorporated into proteins in live cells by
bio-orthogonal aaRS enzymes evolved to bind the UAA and its
unnatural tRNA but not interact with the naturally occurring
amino acids or tRNAs (Figure 1). The unnatural tRNA
recognizes a stop, quadruplet base pair, or frameshift codon
such that this combination manipulates the cell’s endogenous
translational machinery to incorporate the UAA into the target
protein at the specific site of interest.
Chatterjee et al. (Schultz)5 advanced the field by streamlining
multisite UAA incorporation into a simple Escherichia coli
transformation with two plasmids. One plasmid pUltraII
encoded one copy each of two orthogonal aaRS/suppressor
tRNA pairs: amber (UAG) suppressing Methanococcus
jannaschii tyrosyl (MjTyr)-derived aaRS/tRNACUA and opti-
mized ochre (UAA) suppressing Methanosarcina barkeri
pyrrolysyl (MbPyl)RS/Methanosarcina mazei pyrrolysyl
(MmPyl)-tRNAUUA. The second plasmid encoded target protein
green fluorescent protein (GFP) containing amber and ochre
nonsense codons (GFP-3TAG-151TAA) to direct the incorpo-
ration of two unique UAAs into a single protein. This was
previously intractable due to the requirement for multiple copies
of aaRS or tRNA expression cassettes to incorporate a single
UAA. The predecessor of pUltraII, pEVOL, encoded one copy
of a MjTyr-derived optimized amber suppressor tRNA and two
copies of MjTyrRS to incorporate UAAs into GFP151TAG.6,7
With this construct in the presence of UAA p-azido-L-
phenylalanine (pAzF), the suppression efficiency for a single
amber codon reached approximately 80% of that of wild-type
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GFP.7 Incorporation of two UAAs, p-acetyl-L-phenylalanine
(pAcF) and Nε-Boc-L-lysine (eBK), into GFP-3TAG-151TAA
using pUltraII achieved 20−25% of wild-type GFP expression.5
Generality was shown by optimizing incorporation of these
UAA pairs simultaneously into GFP using the amber and ochre
suppressor aaRS/tRNAs: pAcF and azido-L-lysine (AzK), pAcF
and eBK, pAzF, and eBK, andO-methyl-L-tyrosine (OMeY) and
eBK (Figure 2). UAAs with click handles, for example, pAcF and
AzK, were incorporated for dual labeling with dyes suitable for
in-gel Förster resonance energy transfer (FRET). They applied
the dual suppression system to label a nonfluorescent target,
ketosteroid isomerase, with a FRET pair by incorporating acetyl
and azido click handles and labeling with Alexa Fluor 488-
hydroxylamine to label the ketone and Alexa Fluor 594
dibenzocyclooctynol to label the azide, postpurification.5
■ EARLY RESEARCH WITH UAAS
Researchers began exploring the possibility of using modified
tRNAs to incorporate UAAs soon after the discovery of the
tRNA adaptor.8,9 In fact, the tRNA adaptor hypothesis was
proven by chemically reducing Cys-tRNACys to Ala-tRNACys and
showing that Ala would then be incorporated in response to a
poly-Cys template.10 In 1967, it was shown that the translational
machinery could utilize D-Tyr-tRNATyr, prepared enzymatically
by tyrosyl-tRNA synthetase (TyrRS), as a substrate.11 The
flexibility of the ribosomal peptidyl transferase center (PTC) to
unusual chemistry was further shown by Fahnestock and Rich.
They demonstrated that the translational machinery could
synthesize oligomers containing multiple ester bonds using
chemically converted hydroxyPhe-tRNAPhe.12 However, each of
these experiments was only possible because of an idiosyncratic
route to the UAA-tRNA: chemical reduction of Cys, enzymatic
charging of D-Tyr, and hydroxylation of the aromatic Phe
residue. What was missing was a general method for producing
the UAA-tRNA.
Right from the start there was significant interest in being able
to incorporate biophysical probes into proteins using UAA
mutagenesis. There were foundational approaches to the task of
incorporating unique side chains. For instance, Johnson and
colleaguesmodified Lys after it had been enzymatically ligated to
tRNA. Acylation of the Nε-amine of Lys-tRNA
Lys with N-
hydroxysuccinimide ester-azidobenzoic acid generated Nε-
azidobenzoyl-Lys-tRNALys.13 Modified UAA-tRNA interfaced
with endogenous translational machinery and was incorporated
in place of or in competition with endogenous unmodified Lys in
rabbit reticulocyte lysate. Because most target proteins contain
multiple Lys residues, the modification could not be restricted to
a single site, thus resulting in multisite incorporation of the
photoactivatable Lys UAA.13
In 1978, Hecht and co-workers established a general
procedure for the chemoenzymatic aminoacylation of
tRNAs.14 T4 RNA ligase transfers an aminoacyladenylate
moiety from N-blocked (with o-nitrophenylsulfenyl) amino-
Figure 1. Unnatural amino acid (UAA) incorporation.
Figure 2. Chemical structures of UAAs incorporated into GFP-3TAG-
151TAA in Chatterjee et al. (Schultz).5
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acylated P1,P2-bis(5′-adenosyl)diphosphates to tRNAs lacking
the 3′-terminal adenosine. However, a large molar excess (>200-
fold) of aminoacylated nucleotide derivatives were required for
good yields, so they optimized the synthesis such that an only
20-fold molar excess was necessary, using N-acetylaminoacyl
pCpA derivatives instead.15 The modified chemical amino-
acylation was used to acylate tRNAPhewith both D- and L-Phe, D-
and L-Tyr, and N-acetyl-DL-β-Phe. Misacylated tRNAs can
participate in peptide bond formation, consistent with the
adaptor hypothesis, but efficient dipeptide formation with a
poly-Phe message occurred primarily with L-Phe, L-Tyr, and,
interestingly, β-Phe, with L-PhetRNAPhe as the A-site tRNA.15
An alternative approach was demonstrated by Baldini and
colleagues in 1988. Prior to this work, due to protection of the
amino group during pCpA ligation, the chemically misacylated
tRNAs could not bind the ribosomal A site and be incorporated
into a growing polypeptide chain; thus, only dipeptides could
form. By introducing a transient Boc protection/deprotection
into the UAA-tRNA ligation, they demonstrated synthesis of
functional E. coli tRNAPhe charged with a photoactivatable cross-
linker UAA, L-4′-[(3-trifluoromethyl)-3H-diazirin-3-yl]-
phenylalanine.16 However, protein yields were often low due
to the stoichiometric nature of chemically acylated tRNAs, and
modifications were limited because there were no general
methods for UAA-tRNA synthesis. Johnson and Brunner’s
methods both allowedmore flexibility in the range of biophysical
probes that could be attached to either Lys or Phe; however,
they still were not general methods for UAA-tRNA synthesis,
and they led to uncontrolled multisite incorporation of the
biophysical probes.13,16
■ A GENERAL METHOD FOR THE SITE-SPECIFIC
INCORPORATION OF UAAS IN VITRO
A breakthrough was the report of a general method for site-
specific in vitro incorporation of UAAs by the Schultz lab (Figure
3).17 Briefly, they developed a general method for synthesizing
UAA-tRNAs that recognized UAG stop codons and then
demonstrated that this UAA-tRNA could be utilized by a crude
E. coli S30 cell extract for site-specific incorporation of the UAA
in response to a UAG codon engineered in a protein-coding
gene.
The synthesis of the UAA-tRNA was made possible by an
efficient chemical synthesis of the UAA-pdCpA, the two
terminal nucleotides of the tRNA, and by technology previously
developed by Sid Hecht and co-workers that showed UAA-
pCpAmolecules could be efficiently ligated to tRNAmissing the
terminal dinucleotide pCpA at the 3′-acceptor stem by the
natural enzyme T4 RNA ligase.18,19 Brunner’s work enabling
misacylated tRNAs to function in the ribosomal A site made it
possible to form polypeptides and largely avoid hydrolysis of the
amino acyl ester linkage by endogenous aaRSs.16 Drawbacks of
the previous methods were nonselective incorporation of the
UAA and size restrictions on the target protein. Noren’s UAA
mutagenesis approach applied these foundational methods to a
generalized system in which in theory a diverse range of UAAs
could be used to acylate the suppressor tRNA, the suppressor
tRNA could be directed to a specific site by mutagenizing that
position to an amber stop codon, and the size of the protein of
interest was limited only by what could be encoded on a plasmid.
Noren et al. (Schultz) showed the incorporation of three
different UAAs in the active-site residue Phe66 in β-lactamase
and kinetic characterization of these variants. They prepared an
amber suppressor tRNA using anticodon loop replacement of
yeast tRNAPhe and demonstrated this tRNA was not recognized
by the E. coli PheRS in their S30 extract [β-lactamase-
(Phe66TAG), non-acylated tRNACUA, and [
3H]Phe]. No β-
lactamase activity was observed, and there was no band
corresponding to [3H]Phe-incorporated β-lactamase by SDS-
PAGE. Significantly, they showed using [3H]Phe-tRNACUA and
HPLC analysis of trypsin-digested β-lactamase that the [3H]Phe
was incorporated only at position Phe66, demonstrating not
only efficient incorporation of the UAA [3H]Phe in response to
the UAG codon but also that the UAA [3H]Phe was not
scrambled with other natural amino acids.17
Bain and co-workers used a strategy similar to that of the
Schultz group to incorporate L-3-iodo-tyrosine into a 16-residue
Figure 3. General method for site-specific UAA incorporation.
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polypeptide.20 They prepared a semisynthetic, non-hyper-
modified E. coli glycyl tRNACUA nonsense suppressor tRNA
acylated with L-3-[125I]tyrosine and incubated with the message
containing UAG at position 9 in rabbit reticulocyte lysate. The
translation product was purified and sequenced to unambigu-
ously determine the site specificity of incorporation. Nonsense
suppression was due entirely to the added synthetic suppressor
because they could not detect read-through by endogenous
aminoacyl-tRNAs (aa-tRNA).21
General Methods for UAA-tRNA Synthesis. A key issue
continued to be the lack of a general method for synthesizing the
UAA-pdCpA (Figure 4). A key advance was made by Robertson
and Ellman (Schultz) in 1991.22 Unprotected pdCpA was
selectively aminoacylated in high yield with the cyanomethyl
ester (CME) ofN-blocked amino acid and ligated to tRNA. The
photolabile nitroveratryl protecting groups for the α-amine and
side chain functional groups enabled the aa-tRNA to be
deprotected photochemically. This reaction produces high
yields of stable, unblocked aa-tRNA that can be used directly
in a purified translation system. The approach greatly simplified
the synthesis of UAA-pdCpA to one high-yield (76−87%)
step.22
An alternative approach to tRNA aminoacylation was catalytic
RNA, or ribozymes. Natural ribozymes catalyze trans-
esterification reactions of phosphodiester bonds. Szostak and
co-workers isolated catalytic RNAs with acyl transferase activity,
like that of the PTC, from pools of random RNA sequences.
They selected for enhanced transfer of an N-biotinyl-L-
methionyl group from the 3′-end of a donor hexanucleotide,
5′-pCAACCA-3′, to the 5′-hydroxyl group of the ribozyme.23,24
Suga, Szostak, and co-workers generated aaRS-like ribozymes
with two catalytic domains: one that recognizes the amino acid
substrate and self-aminoacylates its 5′-hydroxyl and the other
that binds the tRNA and transfers the aminoacyl group to the 3′-
end. This ribozyme acts as a synthetase that can charge tRNAfMet
with Gln or Phe.25 CME was chosen as a leaving group on the
amino acid because it has no hydrogen bond donors or acceptors
that could interact with the ribozyme. Active RNAs could be
isolated from the pool by selection withN-biotinyl-L-glutaminyl-
CME and subsequent pull-down with streptavidin.25
The Suga lab generalized the ribozyme de novo catalyst for
tRNA acylation using aaRS-like RNA molecules called
Flexizymes (Fx) and mutants thereof.26 They noticed that Fx
recognizes neither the leaving nor the amino group of the
substrate, but rather the aromatic functionality of the amino acid
side chain and the carbonyl group of the ester. To improve
binding, they redesigned substrates incorporating an aromatic
ring in the leaving group. They used dinitrobenzyl ester (DBE)
and the more activated chlorobenzyl thioester (CBT). Because
DBEs are less hydrolytically labile than CBTs, DBEs were used
in further experiments. Enhanced interaction between Fx and
the substrate significantly enhanced tRNA acylation efficiency
and enabled incorporation of citrulline, Nε-acetyl-L-lysine, Nε-
biotinyl-L-lysine, p-iodo-L-phenylalanine, (S)-3-isopropyllactic
acid, and (S)-3-phenyllactic acid into short (nine-amino acid)
FLAG-tagged peptides expressed in an E. coli cell-free translation
system, Protein synthesis Using Recombinant Elements
(PURE),27 by amber-programmed frameshift suppression and
sense codon reassignment (AGU, AAC, and CAG).26 This
breakthrough represented a powerful tool for enhancing the
range of UAAs that could be ligated to tRNAs and incorporated
into polypeptides in vitro.
Expanding the Repertoire of UAAs to Address
Questions of Protein Structure and Function. Another
focus of the field following Noren et al. (Schultz) in 1989 was
pushing the boundaries of what UAA structures and functions
could be incorporated and using these UAAs to address
important protein structure and function questions. Key
questions of enzyme mechanism and protein stability could be
addressed by incorporating unnatural isoelectronic or isosteric
analogues of natural amino acids at sites of interest and
measuring changes in enzyme kinetics and/or protein
denaturation.
Building on earlier work with modified nucleosides and
tRNAs, Ellman and Mendel working with Schultz explored the
tolerance of the translational machinery to changes in the amino
Figure 4. General methods for misacylating tRNA. P.G., protecting group.
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acid structure.28 Specifically, they tested if different UAAs could
be incorporated at position Ala82 in T4 lysozyme (T4L) and
how the UAAs affected the stability of T4L. Ala82 is a surface
residue located between two helices, distant from the active site.
The structure and electronics of the UAA significantly affected
its use as a substrate by the translational machinery. The
incorporation efficiencies were as follows: none detected (ND)
for D-Ala and 30% (suppression efficiency) for lactic acid; N-
alkyl amino acids, <5% for azetidine 2-carboxylic acid, 43% for
pipecolic acid, 24% for N-methyl-alanine, and <5% for N-ethyl-
alanine; α,α-disubstituted amino acids, 28% for cyclopropylgly-
cine and 23% for α-aminoisobutyric acid. Interestingly, changing
the amino acid structure and electronics changed the apparent
yield of protein synthesis; because an E. coli S30 crude cell
extract was used, the mechanism of this decrease in yield could
not be determined at the time. The stabilities of the resulting
UAA-substituted T4L proteins were determined by thermal
denaturation as measured by circular dichroism.28 These UAA
backbone analogues largely changed the stability of T4L as
would be predicted.
Judice and Schultz used UAA incorporation to make more
precise changes in amino acid structure than possible with the
natural amino acids to probe enzyme mechanism.29 Staph-
ylococcal nuclease (SNase) accelerates the hydrolysis of
phosphodiester bonds in nucleic acids approximately 1016-
fold. One hypothesis was that general base catalysis underpins
this enormous rate acceleration where Glu43 in SNase acts as a
general base to activate a water molecule for attack on the
phosphodiester backbone of DNA. However, when Glu43 was
replaced with isoelectronic and isosteric analogues, Arg, S-4-
nitro-2-aminobutyric acid, S-2-amino-5-hydroxypentanoic acid,
aminoethylhomocysteine, and citrulline, differing only by being
poorer bases, the kinetics of SNase were virtually unchanged
relative to those of the wild-type. A significant accomplishment
at the time working with E. coli S30 cell extracts, a structure of
the enzyme substituted with homoglutamic acid at site 43 was
obtained. Combined, the kinetic and structural data suggested
that Glu43 may instead play a structural role, fixing the
conformation of a nearby loop.29
Despite the enormous potential utility of biophysical and
other probes, it was becoming clear that the translational
machinery places constraints on the size of the amino acid side
chain and hence what fluorophores, cross-linking agents, post-
translational modification, or other UAAs could be incorpo-
rated.30 Thus, Cornish, Hahn, and Schultz incorporated a small
ketone handle that could subsequently be modified to form an
oxime or other unnatural linkage to the biophysical probe in
what has come to be called bio-orthogonal labeling.31 They
incorporated keto amino acids 1 (5% suppression efficiency)
and 2 (30% suppression efficiency) in sites Ser44 and Ala82 in
T4L, two sites known generally to give high suppression
efficiencies (Figure 5). Subsequently, they showed that
electrophilic ketoneUAA 2 could be derivatized with fluorescein
hydrazide in T4L Ala82 → 2. Fluorescence spectra of purified
T4L Ala82→ 2 and wild-type T4L both being subjected to the
same labeling conditions with fluorescein hydrazide demon-
strated that only the protein containing the ketone handle was
labeled with the fluorophore.31
Alternate Codons for UAA Incorporation. Another
important area was exploring alternate codons for incorporation
of UAAs. The main challenge of nonsense suppression is the
limited range of nonsense codons: amber (TAG), ochre (TAA),
and opal (TGA). Alternate codons would increase the number
of UAAs that could be incorporated in a single protein. In the
1990s, frameshift codon suppression was explored as an
alternative to nonsense suppression (Figure 6). When the
frameshift does not happen, a termination codon UAA appears
downstream, resulting in truncated protein. If the reading frame
is shifted by suppression of the quadruplet codon with UAA-
tRNA, full-length protein is synthesized.
Using this strategy, frameshift suppressor Ala-tRNAACCU and
Ala-tRNACCUA incorporated Ala into E. coli dihydrofolate
reductase (DHFR), shown by a restoration of enzyme activity
to 40% and 15% of wild-type activity, respectively.32
Repurposing of rare codons was another strategy for expanding
options for UAA incorporation. AGG was used as an alternative
codon for incorporation of the photoactive UAAs p-phenyl-
azophenylalanine, 2-anthrylalanine, 1-naphthylalanine, 2-naph-
thylalanine, and p-biphenylalanine into a polypeptide expressed
in an E. coli S30 extract, where AGG is rare (<3%).33 The Sisido
lab extended this work to incorporate the UAAs nitro-
phenylalanine, 2-naphthylalanine, p-phenylazophenylalanine,
and 2-anthrylalanine into streptavidin (Tyr83 → AGGU)
through frameshift suppression in E. coli S30 extracts.34
CGGG was found to work more efficiently than ACCU in
further studies.35,36
More options for different quadruplet codons were
demonstrated in an E. coli S30 cell extract with nitro-
phenylalanine efficiently incorporated into streptavidin using
the codons AGGU, CGGU, CCCU, CUCU, CUAU, and
GGGU.37 Further utility of this approach was demonstrated by
the incorporation of two UAAs, nitrophenylalanine and 2-
naphthylalanine, into streptavidin using the quadruplet codons
CGGG andGGGU.37 Incorporation of two fluorescent UAAs in
E. coli DHFR was achieved by a combination of quadruplet
codon and amber suppression.38 Specifically, the fluorescent
UAA 7-azatryptophan was incorporated with a CGGG
quadruplet decoding tRNA and acceptor Nβ-dabcyl-1,2-
diaminopropionic acid by amber suppression in E. coliDHFR.38
Sense codon reassignment, or genetic code reprogramming,
has been explored as an alternative to nonsense suppression.
Nonsense codon suppression is limited to two UAAs because
there are only three nonsense codons and one must be used for
translation termination. It would be of enormous practical utility
and would allow fundamental questions about the genetic code
to be addressed if sense codons could be reassigned. Forster,
Tan, Cornish, and Blacklow established the concept of genetic
code reprogramming of multiple, adjacent sense codons by
reassigning three sense codons to UAAs using chemoenzymati-
cally charged tRNAs in a reconstituted translation system
lacking aaRSs.39
Rather than using an E. coli S30 in vitro extract with competing
aa-tRNAs and aaRSs that could hydrolyze noncognate aa-tRNA
pairs and recharge the tRNA with the cognate amino acid, we
made a purified in vitro translation system ourselves based on
published protocols in the ribosome mechanism field. The
UAA-tRNAs were prepared using the chemoenzymatic methods
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being used by the Schultz group at the time. Because it was the
first attempt to modify multiple sense codons, we started with
three conservative side chain modifications: O-methyl-L-serine,
2-amino-4-pentenoic acid (allylglycine), and 2-amino-4-penty-
noic acid (propargyl glycine). Tracking the peptide synthesis
using [35S]Met-tRNA, [3H]Glu-tRNA, and authentic peptide
markers prepared by solid-phase peptide synthesis, translation of
a peptide with five of the sameUAAs in a row was demonstrated.
Finally, translation of a peptide with three different UAAs in a
row each in response to a different sense codon was achieved.
Together, this work showed for the first time that multiple sense
codons could be reassigned allowing for translation of unnatural
oligomers, a direction we argue below will become increasingly
important to the field.
Around the same time, Josephson, Hartman, and Szostak
established ribosomal synthesis of nonribosomal peptide-like
molecules containing 10 UAA side chain analogues by sense
codon reassignment, significantly increasing the number of
UAAs that can be incorporated into a single polypeptide.40 The
Suga lab established the mRNA-encoded incorporation of
multiple, consecutive amino acid analogues for the in vitro
synthesis of unnatural polypeptides using a combination of
frameshift suppression and sense codon reassignment (AGU,
AAC, and CAG) in the Fx/PURE reconstituted translation
system with depleted aaRSs and cognate amino acids.26 The
ability to control installation of multiple UAAs significantly
increased the diversity of peptides that can be synthesized and
screened for therapeutic properties. Suga has gone on to do a lot
of work in this area, for example, incorporating multiple,
consecutive amino acid backbone analogues into the peptide
backbone, including α-hydroxy amino acids,41 Nα-methylated
amino acids,42 and, more recently, D-amino acids43 and β-amino
acids.44 However, to date, sense codon reassignment is limited
to in vitro translation systems.
■ A GENERAL METHOD FOR THE SITE-SPECIFIC
INCORPORATION OF UAAS IN VIVO
To date, UAAs were incorporated into E. coli S30, wheat germ,
or rabbit reticulocyte extracts. Methods developed in the
laboratories of Dougherty and Lester pioneered the use of UAAs
in Xenopus oocytes, where they injected UAA-pdCpA-ligated
tRNA and mRNA encoding the protein of interest with an
amber codon, with a particular focus on eukaryotic ion
channels.45 Specifically, Lummis and co-workers explored the
role of a highly conserved Pro at site 8 (Pro8) in cation-selective
5-hydroxytryptamine type 3 receptors. Pro8 acts as a hinge in the
loop between the second and third transmembrane helices, a
region that interacts with the extracellular ligand binding
domain and was hypothesized to play an important role linking
neurotransmitter binding to channel gating through cis−trans
isomerization of the protein backbone. Incorporation of Pro
analogues favoring the cis conformer produced functional
channels, while those favoring the trans conformer produced
nonfunctional channels. Importantly, the cis−trans energy gap of
the Pro analogue was strongly correlated with channel
activation, suggesting cis−trans isomerization of this single Pro
acts as a gating switch between open and closed channel states.45
These experiments built upon their earlier work optimizing the
pdCpA ligation chemistry for backbone analogues, such as α-
hydroxy amino acids.46
With respect to expanding the repertoire of codons for
incorporation of multiple UAAs in Xenopus, Rodriguez and co-
workers demonstrated multisite incorporation of UAAs into
nicotinic acetylcholine receptors by combining nonsense and
frameshift codon suppression.47 A limitation of chemoenzymati-
cally charged tRNAs is that they cannot be reacylated once
inside the cell, capping the amount of protein that can be
generated. An ideal system would include all of the necessary
components genetically encoded in the cell. A main challenge of
eukaryotic genetic code expansion is the fact that translational
machinery is not well conserved between prokaryotes and
eukaryotes.
Figure 6. Alternate codons for UAA incorporation. Frequency data from https://www.genscript.com/tools/codon-frequency-table.
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The next big breakthrough in the field was full genetic
encoding of UAA incorporation components in live cells. In
2001, Wang et al. (Schultz) reported a general method for
incorporating UAAs into proteins in E. coli through directed
evolution of an orthogonal aaRS/tRNA pair.48 This advance
addressed multiple technical challenges in the field. One, it
addressed the technical difficulty of preparing the aminoacyl-
tRNA chemoenzymatically. Two, it removed the limit on
protein yield imposed by use of an in vitro translation extract.
Significantly, the UAA technology could now be adopted by a
non-expert in the technology.
The key conceptual advance was the positive and negative
selection strategy for evolving the orthogonal tRNA and aaRS.49
The naturally orthogonal MjtRNACUA
Tyr and MjTyrRS were used
as the starting point. First, they used a negative selection based
on suppression of a UAG codon in the toxic RNase Barnase in
the absence of MjTyrRS to select for MjtRNACUA
Tyr variants that
could not be aminoacylated by the endogenous natural aaRS
enzymes.49Next, the winners were subject to a positive selection
forMjtRNACUA
Tyr variants that could suppress amber mutations in
β-lactamase in the presence of MjTyrRS.49 Finally, to generate
the orthogonal MjTyrRS, E. coli cells were transformed with a
library of MjTyrRS genes and subjected to a positive selection
for suppression of a UAG codon in chloramphenicol
acetyltransferase (CAT). The library was subject to both
positive (+UAA, +chloramphenicol) and negative selection
(−UAA, +chloramphenicol) to yield pairs that incorporate the
UAA but not natural amino acids in response to the UAG codon.
They used the resulting orthogonal aaRS/tRNA pair to
incorporate O-methyl-L-tyrosine into DHFR expressed in E.
coli.48
While still limited by the need to purify the UAA-incorporated
protein out of the cell, this work eliminated the problem of low
protein yields with in vitro cell extracts and broadly enabled
engineering UAA biosynthetic machinery in live cells.48 There
were some hurdles in getting there, with different selection
approaches being less successful.50 Once a general method for
generating mutant aaRS-tRNA pairs was established, issues that
needed to be addressed were how to generate new orthogonal
aaRS-tRNA pairs for UAA incorporation in model systems
where large mutant libraries cannot be made, such as
mammalian cells, and the lack of suitable starter aaRS−tRNA
pairs orthogonal in these systems. The transfer of E. coli TyrRS-
tRNACUA and LeuRS-tRNACUA to yeast and mammalian cells
was feasible; however, tRNA expression was a major hurdle at
the time. The Wang lab developed a general method for
expressing orthogonal tRNAs in mammalian cells using type 3
Pol III promoters, and this is the general method currently being
used in the field for UAA incorporation in yeast, mammalian
cells, and various animals.51 Another challenge was that the size
of the aaRS binding pocket limited the stereochemical diversity
of UAAs that could be incorporated. A breakthrough in the field
was made by the Wang lab with the finding that mutation of the
Methanosarcina PylRS binding pocket can generate more flexible
substrate specificity for Phe and Tyr analogues with bulky
conjugated rings or long azobenzene side chains.52
The Schultz lab demonstrated the first fully genetically
encoded UAA incorporation system in eukaryotes when they
incorporatedUAAs in Saccharomyces cerevisiae.53They exploited
the fact that E. coli tyrosyl tRNACUA can be expressed in yeast
and is a poor substrate for the S. cerevisiae aaRSs. They evolved
TyrRS in yeast for incorporation of acetyl, benzoyl, azido, and
iodo-Phe analogues, as well as O-methyl-L-tyrosine, into human
superoxide dismutase.53 This system became the basis for
directed evolution of aaRSs for UAAs that could be readily
transferred to mammalian cells. Genetic encoding of orthogonal
synthetase−tRNA pairs in mammalian cells and animals,
including Caenorhabditis elegans, Drosophila melanogaster, and
Mus musculus, followed suit.54−60
Incorporation of UAAs into Mammalian Cells and
Animals. As early as 2006, Tirrell and Schuman established
metabolic labeling with click handle UAAs as a nonspecific,
heterogeneous multisite UAA incorporation method for tagging
newly synthesized proteins in mammalian cells.61 Azidohomoa-
lanine (AHA) is an azide-bearing methionine analogue that can
be incorporated at methionine codons and tagged with an
alkyne-affinity tag using copper-catalyzed azide-alkyne [3+2]
cycloaddition for the identification of AHA-labeled proteins via
mass spectrometry.61 Another methionine surrogate, alkyne-
bearing homopropargylglycine (HPG), was used in tandemwith
AHA to fluorescently label newly synthesized proteins in rat
hippocampal neurons by strain-promoted cycloaddition.62
Pulse-chase experiments enabled fluorescent labeling of two
distinct proteomes synthesized sequentially in time such that the
dynamics of protein synthesis and fate could be monitored in
neurons.62 Thus, they could address important questions about
the role of newly synthesized proteins in neuron function
without the need for selective incorporation of the UAA.
Efficient incorporation of UAAs into proteins in animals has
also been a critical challenge. To improve the efficiency, many
different methods have been researched, including using the
type 3 polymerase III promoter to more efficiently express
orthogonal prokaryotic tRNAs,51 UAA esterification to increase
UAA bioavailability,63 and optimizing tRNA/synthetase affinity
to increase the level of UAA incorporation.64 Encouraging
progress was achieved in this research area through the
combined use of these optimized methods.4 In their letter to
the editor ofCell Research, Ye,Wang, Li and co-workers reported
the introduction, maintenance, and transmission of the genetic
material for code expansion inmice. In this work, they integrated
the orthogonal pAzFRS/tRNACUA pair into the mouse
genome.59 They demonstrated that, in the presence of pAzF,
the suppressor tRNA can decode the UAG amber codon to
express a dual fluorescent reporter eGFP-TAG-mCherry in
neurons and bone marrow cells of mice.59
Expanding the Repertoire of UAAs That Can Be
Incorporated In Vivo. One of the most exciting classes of
UAAs continues to be backbone analogues because of the
potential to extend the power of genetic encoding to oligomers
other than α-L-polypeptides. The logic of making backbone
analogue UAA incorporation work in vivo began with the
discovery or generation of ribosomes that can accommodate
these UAAs followed by testing of known aaRS/tRNA pairs for
charging them. In 2016, Schepartz and Söll incorporated β3-
amino acids into full-length DHFR in E. coli.65 Previously,
Dedkova and Hecht had found that ribosomes from some
erythromycin-resistant E. coli mutants could tolerate the
incorporation of β3-amino acids into full-length DHFR in
vitro.66 Building on this work, Schepartz and Söll highlighted the
unexpected flexibility of the endogenous E. coli translational
machinery to β3-amino acid backbone analogues when they
demonstrated incorporation of β3-amino acids into DHFR
expressed in E. coli harboring a plasmid encoding mutant
ribosomes from erythromycin-resistant strains.65 Significantly,
they demonstrated that β3-(p-Br)Phe and β3-Gly could be
charged by endogenous aaRS enzymes, with PheRS being the
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most tolerant of these substrates. Furthermore, wild-type EF-Tu
interacted efficiently with β3-Phe-tRNAPhe for delivery to the
ribosome. To improve the efficiency and selectivity for β3-amino
acid incorporation, a library of peptidyl transferase center 23S
rRNA mutant ribosomes were screened for erythromycin
resistance and β-puromycin sensitivity, resulting in a new
mutant P7A7 that imparted 3-fold higher levels of β3-amino acid
incorporation over those of the previously discoveredmutants.65
Tryptic digest of DHFR peptide fragments containing either α-
Phe or β3-(p-Br)Phe at F128 showed a 10-fold lower level of
incorporation of the β3-amino acid versus α-Phe.65
Underscoring the importance of recent work incorporating
backbone analogue UAAs in vivo, it has been difficult for
scientists to produce peptides containing D- and β-amino acids
by UAA incorporation in vitro. By tuning tRNA sequence and
concentrations of native initiation (IF2) and elongation factors
(EF-Tu/Ts and EF-G), in 2017, the Suga lab increased the yield
of a D-Ala-D-Ala-containing peptide by >5-fold and incorporated
10 consecutive D-Ser residues into a peptide chain.43 The
existence of mutant E. coli ribosomes that enhance D-amino acid
incorporation in vitro indicates potential for in vivo incorpo-
ration of D-amino acids.67 Similarly, in 2018, the Murakami lab
improved incorporation of multiple β-amino acids, producing
peptides with natural amino acid spacers between two or three
β-amino acids in their optimized translation system.68 Trans-
lating the in vitro advances in incorporation of backbone
analogue UAAs to cells should catch on as more suitable aaRS/
tRNA pairs are established. In 2019, Dedkova and Hecht found
that wild-type PylRS could incorporate a fluorescent oxazole
UAA lacking an asymmetric center or α-amino group. MreB
(Leu13TAG) was co-expressed with PylRS in an E. coli strain
with modified ribosomes that could incorporate dipeptides and
dipeptidomimetics.66,69 It is becoming clearer howmalleable the
translational machinery is for incorporation of more exotic
UAAs. Importantly, this research signals the possibility of
finding more mutant ribosomes and aaRS/tRNA pairs for
backbone analogue UAA incorporation in vivo. One direction
the field is going is to combine an expanded pool of UAA
backbone analogues with an expanded pool of orthogonal
codons and engineered orthogonal ribosomes for genetic
encoding of unnatural oligomers in vivo.
Another class of UAA analogues that could be highly
impactful is epigenetic protein modifications. Research on the
functional effects of specific epigenetic protein modifications is
hindered by the difficulty of synthesizing post-translationally
modified target proteins in cells. O-phosphoserine (Sep) is the
most abundant phosphorylated amino acid in eukaryotes. It is
synthesized post-translationally by acylation of tRNACys with
Sep by SepRS, an aaRS unique to methanogenic archaebacteria.
Park et al. (Söll, Noren, and Rinehart) made an amber
suppressing tRNASep and, critically, evolved an EF-Tu mutant,
EF-Sep, that could bind Sep-tRNASep for site-specific incorpo-
ration of Sep into proteins in E. coli.70 SepRS, tRNASep, and EF-
Sep together allow E. coli to read UAG as a Sep codon; they
synthesized mitogen-activated ERK activating kinase 1 (MEK1)
with Sep incorporated at a key modified residue Ser218 by
amber suppression in vivo.70 In addition, it would need to be
established that Sep was incorporated at only the intended UAG
residue. Similarly, tyrosine phosphorylation is a critical PTM in
cellular signal transduction. In 2017, Luo et al. (Schultz and
Wang) incorporated O-phosphotyrosine (pTyr) and its non-
hydrolyzable analogue, 4-phosphomethylphenylalanine, into
recombinant proteins by amber suppression in E. coli.71 Around
the same time, Hoppmann and co-workers (Hunter, Shokat, and
Wang) incorporated a neutral pTyr analogue into recombinant
proteins in E. coli by amber suppression; deprotection results in a
native, negatively charged pTyr at the desired site.72 Multisite
incorporation of these UAAs would enable modeling of multiple
phosphorylated residues of a protein.71,72
Low yield is a significant hurdle to studying proteins modified
with UAAs by amber suppression in vivo. Wild-type expression
levels of UAA-modified protein cannot be realized because
suppressor tRNAs compete with release factors (RFs) for the
stop codon. Church, Isaacs, and co-workers have pioneered the
breakthrough in this area by developing genomically recoded
organisms (GROs). Upon recoding of the entire genome of E.
coli such that all UAG stop codons are mutated to the UAA stop
codon and deletion of RF1, the “blank” UAG codon could then
be reintroduced as a sense codon for highly efficient
incorporation of a UAA.73 The new genome enabled this new
strain of E. coli C321.ΔA to exhibit increased resistance to viral
infection by blocking the translation of viral proteins.73 The
Church lab has led this area of research toward creating GROs
with expanded capabilities. Ostrov and co-workers (Church)
created E. coli with a 57-codon genome in which all 62214
instances of seven codons were replaced with synonymous
codons in all protein-encoding genes.74 When the recoded
codons’ respective tRNAs and release factor are removed, up to
four orthogonal UAAs could be introduced into the organism.74
The increased yield and specificity of UAA incorporation in
GROs should empower efforts for industrial UAA-modified
protein production and more representative in vivo experiments
with UAA-modified proteins.
The genomically recoded E. coli strain C321.ΔA has been
used subsequently to advance techniques for studying post-
translational modifications with UAAs. Isaacs and Rinehart
conducted a proteome-wide investigation of the role of
phosphorylation of human proteins in vivo.75 They genetically
encoded Sep70 in a synthetic human phosphopeptide library
expressed in C321.ΔA and identified proteome-wide phosphor-
ylation-dependent interactions using bimolecular fluorescence
complementation in cells.75 In contrast, for in vitro studies of the
regulation by phosphorylation of 26S proteasome subunit RpnI,
Sep was incorporated into RpnI(361TAG) expressed in E. coli
strain C321.ΔA, allowing for purification of homogeneously
phosphorylated RpnI.76 To transfer this technology to
mammalian cells, Chin and co-workers demonstrated orthogon-
ality in mammalian cells of an evolved SepRS/tRNACUA pair
77
based on the original by Park and co-workers.70,78 The Sep
incorporation system in mammalian cells was completed by co-
expression with eRF1(E55D) (a eukaryotic RF more permissive
of UAG read-through), creation of a eukaryotic elongation
factor variant EF-1α-Sep containing mutations analogous to
those of the prokaryotic EF-Sep, and deletion of phosphoserine
phosphatase to increase the intracellular Sep concentration.78 If
the UAA technology can be used to selectively introduce Sep
(and ultimately other epigenetic modifications simultaneously)
at multiple, defined positions in a single protein in living cells,
this will be a very powerful tool for biologists.
Fluorescent UAAs remain one of the most sought after yet
challenging classes of analogues. Tagging with fluorescent
proteins (FP) is an indispensable technique for localization and
mechanistic studies of protein targets inside cells. However, the
large size of FPs (27 kDa) limits tagging to the protein termini
and the targets that can be studied. The most efficient chemical
tags also require protein tags, and the peptide chemical tags rely
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on two-step labeling with bio-orthogonal chemistry. The holy
grail of fluorescent labeling would be direct and selective
incorporation of a fluorescent UAAwith a high photon output in
mammalian cells. The challenges are having the ribosome accept
a large fluorophore as a substrate, minimal nonspecific labeling
of the fluorescent amino acid in the cell or incorporation into
other UAG codons, or rapid and selective bio-orthogonal
chemistry; one indication that the labeling technology meets
these criteria is that it can be used to image a typical cellular
protein at ∼1 μM concentrations freely diffusing intracellularly
with single-molecule resolution. Comprehensive reviews of this
literature have been published,79,80 and we have highlighted
advances in this field and the related chemical tagging field
previously.81 Here we focus on the significant challenge of
efficient and robust fluorescent labeling of intracellular proteins
in mammalian cells, highlighting the systematic comparison of
fluorescent UAA labeling by bio-orthogonal click chemistry
technologies from Peng and Hang.82 While there has been
success in labeling intracellular proteins in live mammalian cells
using bio-orthogonal strain-promoted click chemistry,83,84 the
majority of published work still focuses on cell surface proteins.
Peng and Hang wanted to observe the localization and
trafficking of the small membrane-associated protein interfer-
on-inducible transmembrane protein 3 (IFITM3) in cells. Given
that GFP is twice the size of IFITM3, they took advantage of the
small size and modularity of organic fluorophores afforded by
the UAA technology. Site-specific incorporation of the
commercially available trans-cyclooct-2-ene lysine (2′-
aTCOK) into IFITM3 by amber suppression with the
MmPylRS(Y306A, Y384F)AF/tRNA pair85−87 led to the most
efficient and specific labeling with monosubstituted tetrazine
(Tz) fluorophores, e.g., tetrazine silicon rhodamine (H-Tz-SiR),
in live mammalian cells (Figure 7).82 H-Tz-SiR was the best all
around for intracellular labeling; H-Tz-BODIPY-FL was good
but is more appropriate for membrane protein labeling due to its
relative hydrophobicity.82
The alternative to bio-orthogonal click chemistry labeling is
direct incorporation of a fluorescent UAA. The benefit of this
approach is ease. All that is required is transfection of the aaRS/
tRNA and target constructs, incubation with the UAA, and
washing out excess UAA. The drawbacks are the limitations on
the size of the fluorescent side chain due to the aaRS binding
pocket and, thus, the tendency for these fluorophores to be
relatively blue-shifted and dim. Nonetheless, site-specific
fluorescent labeling of proteins with fluorescent UAAs is built
on the foundation of direct incorporation of a single fluorescent
amino acid. Jan and Cohen established the state of the art with
their incorporation of environmentally sensitive fluorescent
UAA Aladan into the B1 domain of streptococcal protein G
(GB1) by solid-phase synthesis.88 The small size, the flexibility
of the incorporation site, and the keen environmental sensitivity
of Aladan provide unparalleled spatial resolution for detecting
the electrostatic properties of various regions of this protein.88
In vivo incorporation of Aladan analogues, such as Anap, was
enabled by the establishment of aaRS/tRNA pairs for this UAA,
derived from E. coli LeuRS/tRNACUA.
89 Anap undergoes a blue-
shift in fluorescence emission in increasingly hydrophobic
environments, making it promising as a sensor of protein
conformational change. Shandell, Cornish, and Kass demon-
strated the feasibility of sensing the conformational change of a
population of UAA-modified cardiac voltage-gated sodium
channels expressed in live mammalian cells through incorpo-
ration of Anap into the inactivation gate, a dynamic ∼50-amino
acid intracellular linker.90 Since the foundational work of
Dougherty and Lester, ion channel physiologists have embraced
the UAA technology in oocytes.91,92 Significantly, Puljung and
co-workers incorporated Anap into KATP channels in live
mammalian cells, enabling voltage-clamp fluorimetry experi-
ments in this new, possibly more physiologically relevant
context.93 Ligand binding or conformational change measured
by Anap environmental sensitivity can now be coupled to
functional changes in channel gating measured by electro-
physiology in mammalian cells.93More impactful applications of
the technology are being published as technical challenges are
overcome and efficiency and ease of use improved. When
multiple fluorophores with single-molecule resolution can be
incorporated selectively into mammalian cells, the UAA
technology will be a powerful tool for studying biological
mechanism in living cells.94
■ NEW CONCEPTUAL APPLICATIONS OF UAA
INCORPORATION
Wonderfully creative, the UAA technology will inspire myriad
new directions. One particularly expansive direction is to
engineer not only the amino acids but also the nucleic acids,
organelles, and other parts of the cell to give rise to unnatural,
chimeric, and semisynthetic organisms (SSOs). In some ways,
this is the counterpart to building an artificial cell ground up
from artificial RNA parts.95 To model biological conditions that
could explain the transition from an RNA world, Schultz and co-
workers engineered chimeric E. coli in which 40% ribonucleotide
versus deoxyribonucleotide could be incorporated into the
genome when the size of the pool of deoxyribonucleotide
triphosphates in the cell was significantly decreased in concert
with defects in DNA repair.96 In a similar fashion, Schultz and
co-workers modeled the central hypothesis of endosymbiotic
theory that mitochondria could have evolved from prokaryotes
entering host cells and being maintained as endosymbionts.
They engineered chimeras of E. coli and S. cerevisiae in which
Figure 7. Ideal UAA incorporation components and fluorescent click
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mutant E. coli live in the cytosol of and provide ATP to a
respiration-deficient yeast mutant or yeast provide thiamin to a
resident E. coli thiamin auxotroph.97 SSOs can be generated by
codons containing unnatural base pairs or through the
engineering of sense codon usage. Zhang et al. described an
optimized SSO that stores genetic information using DNA
containing two additional letters, which form a third, unnatural
base pair, dNaM (mRNA codon) and dTPT3 (tRNA
anticodon).98 This expanded genetic code enables decoding of
new codons to direct site-specific incorporation of UAAs into
proteins in E. coli.98 Recently, the Chin lab announced the
creation of a SSO with a 61-codon genome. Creation of such a
synthetic, minimally recoded E. coli genome by compressing
synonymous codons addresses origins of life questions and
biological mechanism and is enormously useful for therapeutic
applications.99
Mechanistic Studies of Translation with UAAs. Some-
what surprisingly, there has been little integration of the
incredible advances in our understanding of the structure and
mechanism of the translational machinery and the UAA
technology since the breakthrough publication by Noren et al.
(Schultz) in 1989. It has often been thought that natural
limitations of the translational machinery underlie the difficulty
in incorporation of D- and β-amino acids. It turned out that the
translational machinery may be more tolerant to unnatural
substrates than previously thought.Mechanistic insight into how
these analogues interfere with translational machinery was
needed. Leyh, Gonzalez, Cornish, and co-workers further
clarified the mechanism by which D-amino acids disrupt
translation in a purified translation system, finding that while
D-aa-tRNA can be accepted at the A site, act as a peptidyl-
transfer acceptor, and translocate the peptidyl-D-aa-tRNA into
the P site, this process occurs slowly.100 Furthermore, the
peptidyl-D-aa-tRNA at the P site partitions ribosomes into
arrested and non-arrested subpopulations. Chemical protection
and molecular dynamics simulations demonstrated that P-site-
bound peptidyl-D-aa-tRNA traps the PTC in a conformation
that is not conducive to peptidyl transfer, providing insight into
how the ribosome discriminates between L- and D-amino
acids.100 This mechanism of discrimination against D-amino
acids appears to be similar to other peptide stalling mechanisms
of the ribosome and may suggest the mechanism by which it
discriminates against UAAs generally. Further mechanistic work
with UAAs no doubt would lead to additional mechanistic
surprises and could significantly inform efforts to improve the
efficiency and breadth of the technology.
Engineering Multisite UAA Incorporation In Vivo.
Whether the objective is to incorporate different epigenetic
modifications or to synthesize an unnatural backbone oligomer,
it will be critical to be able to incorporate multiple different
UAAs in vivo using alternate codons. Yields of UAA-
incorporated proteins expressed in mammalian cells are
significantly lower than those expressed in E. coli. Thus, it is
an uphill battle to yield multiply UAA incorporated proteins in
mammalian cells. In 2013, Chatterjee et al. (Schultz) developed
a baculovirus-based delivery system for efficient incorporation of
UAAs into proteins in mammalian cells.101 Later that year, the
samemammalian suppression systemwas applied to incorporate
two distinct UAAs (eBK and OMeY) into EGFP in HEK293T
cells using TAG and TAA suppression with EcTyrRS/tRNACUA
and MbPylRS/MmtRNAUUA pairs, respectively. They also
demonstrated the application of dual suppression to fluorescent
labeling of antibody−drug conjugates (anti-Her2-IgG-nAF)
purified from HEK293F cells.102 In mammalian cells, nonsense
suppression suffers from a low level of expression of suppressor
tRNAs and competition with endogenous release factors seeking
to truncate target protein. In 2011, Johnson and co-workers
established that knockout of release factor 1 in E. coli enables
Figure 8. Bio-orthogonal translation with orthogonal and tethered ribosomes.
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incorporation of UAAs at multiple TAG sites in the same
gene.103 In mammalian cells, by optimizing the PylRS/tRNACUA
expression system and engineering eukaryotic release factor 1,
Schmied and co-workers were able to increase the yield of
protein containing UAAs at three sites by 2−4-fold.104Multisite
incorporation at unique codons selectively in vivo remains a
challenge for the field.
Engineering the Ribosome for Improved Incorpora-
tion of UAAs. One strategy toward multisite UAA incorpo-
ration at unique codons is to take advantage of our growing
structural and mechanistic understanding of the translational
machinery to engineer the ribosome itself. When the toolbox is
expanded to include both quadruplet and amber codons, the
ability of the natural ribosome to decode such codons limits the
efficiency of UAA incorporation and the resulting yield of UAA-
incorporated protein. It has been an outstanding challenge
incorporating multiple UAAs in a single protein even in E. coli
expression systems due to the lack of several blank codons and
mutually orthogonal aaRS/tRNA pairs. In a breakout
publication, Rackham and Chin addressed this challenge by
engineering an orthogonal ribosome in E. coli via an engineered
duplicate, orthogonal Shine-Dalgarno mRNA sequence/16S
small ribosomal subunit RNA pair.105 Building on this work,
Chin and co-workers have evolved an orthogonal ribosome for
quadruplet and amber decoding.106 Orthogonal ribosomes can
be devoted to efficient decoding of alternative codons because
they are directly targeted to a corresponding orthogonal mRNA
and thus do not synthesize the proteome. Through the
combined use of mutually orthogonal aaRS/tRNA pairs, the
evolved ribosome, and corresponding orthogonal mRNA, two
UAAs were incorporated into single recombinant fusion
proteins in E. coli. The cross-linking UAA p-benzoylphenylala-
nine (Bpa) and click handle pAzF were incorporated into
glutathione S-transferase (GST)-maltose binding protein in
response to a quadruplet and amber codon. The alkyneN6-[(2-
propynyloxy)carbonyl]lysine (CAK) and pAzF were incorpo-
rated into GST-calmodulin in response to a quadruplet and
amber codon.106 Incorporation of pAzF and CAK into
calmodulin enabled formation of a triazole cross-link by
copper-catalyzed click chemistry, demonstrating precise genetic
control of protein conformation with the UAA technology.
Early strategies for achieving orthogonality involved the
development of orthogonal aaRS/tRNA pairs, building of
orthogonal genetic codes, and creation of orthogonal
ribosome−mRNA pairs by engineering the 16S rRNA and
complementary mRNA Shine-Dalgarno sequences.107 How-
ever, the continuous exchange of the subunits of the ribosome
still limits the establishment of complete orthogonality with
native translation (Figure 8). To address this gap, Jewett and
Mankin used a circular permutation approach to systematically
generate linked 16S−23S rRNA variants that could assemble
functional tethered ribosomes in cells.108 They demonstrated
that the engineered ribosome with inseparable tethered subunits
(Ribo-T) is capable of supporting the growth of E. coli cells,
wholly orthogonal, and does not interfere with wild-type
ribosomes.108,109 They demonstrated the unique utility of
Ribo-T in studying dominant lethal mutations of rRNA, a nearly
impossible task in other cell models.108 The Chin lab used a
similar approach to covalently link the small and large ribosomal
subunits by RNA linkers.110,111 The compatibility of the
tethered ribosomal complexes with the multisite incorporation
of UAAs was evaluated by Jewett and Mankin through the
fluorescence analysis of a super folder GFP (sfGFP) variant
containing five TAG codons, finding that the tethered
translation system is effective in incorporating five pAzF click
handles into sfGFP.112What remains is to show incorporation of
multiple different UAAs in a row, each in response to a different
codon.
Application of UAA Technology to Biomedicine. The
UAA technology is ideal for antibody−drug conjugate (ADC)
generation and other applications in biomedicine. The problem
is production of homogeneous titers of ADCs for targeted
cancer chemotherapy. ADCs are anticancer therapies designed
to target tumors with cytotoxic small molecule drugs. Bypassing
normal tissues reduces the toxic side effects of chemotherapy.
Site-specific conjugation of the small molecule drug to the
antibody homogenizes the mixture of ADCs, thus providing
more reliable pharmacokinetic properties, efficacy, and safety
profiles. In 2014, Tian and co-workers produced gram per liter
scale titers of UAA-incorporated ADCs from stable CHO cells
using antibodies targeting common antigens on colorectal/
gastric and breast cancers.113 Ambrx, Inc., developed an anti-
HER2 ADC product ARX788 using the UAA incorporation
strategy. ARX788 is generated by the formation of a highly stable
oxime bond between a noncleavable Amberstatin (AS269) drug
linker and a ketone-bearing UAA, pAcF, which was incorporated
into the primary sequence of the antibody through amber codon
suppression. The Food and Drug Administration has granted
fast track designation to ARX788 for the treatment of patients
with advanced or metastatic HER2-positive breast cancer in
2021.114
UAAs can also be used for vaccine development. In 2014,
Wang and co-workers developed a theoretically safe and
effective HIV-1 vaccine by making viral replication dependent
on the presence of UAA and the aaRS/tRNA pair.115 In 2016,
the Zhou lab developed a live attenuated influenza A vaccine
strain containing multiple amber codons in its genome.116 The
strain can be replicated only in a transgenic 293T cell line that
harbors an orthogonal amber suppressor aaRS/tRNACUA pair
and the cognate UAA, making it replication incompetent in
normal human cells and thus useful for immunization.116
Undoubtedly, the UAA technology can be exploited in other
modalities for therapeutics.
Studying Fundamental Biological Processes with UAA
Technology. Once multiple different UAAs can be incorpo-
rated at unique codons in vivo with no cross reactivity, the UAA
technology will be a powerful tool for systems biology that
enables biological mechanism to be studied in living cells. As an
example, biologists would like to control various protein
signaling states by turning on and off receptor−ligand
interactions and intraprotein interactions. Such control would
enable clear-cut conclusions about the functional effects of
specific protein structures in the native cell environment. This
was recently illustrated in a study by the Chen lab exploiting
transition metal-based bio-orthogonal cleavage reactions for on-
demand release of toxic drugs from ADCs and precise control of
ligand−receptor interactions at the cell surface.117 In this study,
they used the genetic code expansion strategy to incorporate
chemically caged Tyr and Lys analogues into eight different sites
of ZHer2, a small protein with a high affinity for the membrane
protein HER2. The UAA-modified ZHer2 mutants were ex-
pressed in E. coli, purified, and fluorescently labeled. Fluorescent
ZHer2 and its UAA-modified mutants were incubated with SK-
BR-3 cells, a human breast cancer cell line that overexpresses
HER2, and analyzed by flow cytometry. Strong fluorescence was
observed when wild-type ZHer2 andHER2 interacted. A decrease
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in fluorescence was observed with caged UAA-modified ZHer2
mutants that could no longer interact. Fluorescence was rescued
upon decaging to the native amino acid. This allowed them to
directly probe the functional role of each amino acid residue in
the interaction between ZHer2 and Her2.
117 It should be
emphasized that the UAA technology is at a sufficiently mature
stage where it can be adopted by biologists not expert in the
methodology with similar ease and with even more diverse
applications, perhaps, than GFP.
■ FUTURE DIRECTIONS
Considerable progress has beenmade in the field of genetic code
expansion since the publication of the study by Chatterjee et al.
in 2013. However, many technical challenges remain, and the
application of the technology to drug development and basic
science is only just beginning.
Significantly changing the structure of the amino acid and still
having it be accepted as a substrate by the translational
machinery remains difficult. For example, there are limitations to
what backbone analogues can be incorporated for unnatural
oligomer synthesis or powerful fluorophores for biophysical
studies of proteins. There have been incredible advances in our
understanding of ribosome structure and function since Schultz,
Noren, and co-workers published their seminal paper in 1989. In
collaboration, we demonstrated that this mechanistic knowledge
could be exploited to gain insight into how the translational
machinery discriminated the structure and electronics of the
amino acid. More mechanistic work with UAAs is needed. This
mechanistic work can provide insight into the mechanism of
translation and guide future engineering efforts. It also is now
possible to engineer translation and the ribosome at a scale not
previously possible with GROs, stapled ribosomes in vivo, and a
growing arsenal of UAAs. Together, these advances allow direct
selection for orthogonal ribosomes that work with an expanded
set of UAAs and codons.
Optimization has made expression and purification of UAA-
incorporated proteins from E. coli a robust method accessible to
scientists not expert in the field. Biochemists and biologists are
encouraged to adopt the technology and apply it to a variety of
mechanistic questions. With the ability to produce a broad range
of UAA-containing proteins in E. coli in high yield and advances
in bio-orthogonal labeling methods, the field is at an exciting
moment to apply the technology to challenging problems in
drug discovery and biotechnology. Antibody−drug conjugates
and vaccine development likely are just the start for therapeutic
applications of the technology. Undoubtedly, an important next
step for the field will be synthesizing unnatural oligomers
directly in E. coli.
The next challenge is to develop methods for incorporating
multiple, different UAAs in response to different codons in live
mammalian cells. This would allow mechanistic questions, like
the role of different epigenetic modifications, to be addressed
directly in the cell. Technically, this likely will require (1) using
GROs so the UAAs are not incorporated at endogenous codons,
(2) engineering tethered ribosomes in mammalian cells, and (3)
evolving tethered ribosomes to work with different UAAs and
different codons. If successful, like GFP before it, UAAs could be
a powerful tool for studying biological mechanism in live cells,
but with a much broader repertoire of chemical functionality.
■ CONCLUSION
The incorporation of unnatural amino acids by the translational
machinery using artificial UAA-tRNAs is a wonderfully creative
idea bringing together organic chemistry, molecular biology, and
synthetic biology of the translational machinery. It is now a
robust field with many who trained in the technology leading
their own exciting advances for the tools in the UAA repertoire,
in the aaRS/tRNA orthogonal pairs, in moving to higher
organisms, and even in tethered orthogonal ribosomes and de
novo GROs. Looking forward, as the tools continue to progress,
UAA mutagenesis no doubt will become an essential tool for
asking fundamental questions in systems biology and will be
further adapted as a new strategy for drug development.
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